Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -26.37% is 60% above its 5-year average of -66.09%, around the middle of its 5-year range (-410.09%–166.09%).
As of the fiscal period ended Tuesday, June 30, 2026. 3653.81% below its 12-month average of 0.74%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -26.37%.
RETURN ON EQUITY (ROE)
-26.37%
RETURN ON EQUITY (ROE) AVG TTM
0.74%
RETURN ON EQUITY (ROE) AVG 3Y
28.30%
RETURN ON EQUITY (ROE) AVG 5Y
-66.09%
RETURN ON EQUITY (ROE) AVG 10Y
-73.01%
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
-3653.81%
CURRENT VS 3Y AVG
-193.18%
CURRENT VS 5Y AVG
+60.10%
CURRENT VS 10Y AVG
+63.88%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-38.55%
median of 491 covered companies
CURRENT VS SECTOR MEDIAN
+31.60%
vs the sector median at left
CytomX Therapeutics, Inc.
Market Cap
$557.41M
Return on Equity (ROE)
-26.37%
TTM Avg
0.74%
3Y Avg
28.30%
5Y Avg
-66.09%
Market Cap
$560.00M
Return on Equity (ROE)
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$564.07M
Return on Equity (ROE)
40.62%
TTM Avg
9.52%
3Y Avg
-25.24%
5Y Avg
-32.61%
Market Cap
$566.48M
Return on Equity (ROE)
N/A
TTM Avg
161.13%
3Y Avg
93.89%
5Y Avg
96.07%
Market Cap
$570.28M
Return on Equity (ROE)
N/A
TTM Avg
44.05%
3Y Avg
44.05%
5Y Avg
44.05%
Market Cap
$541.64M
Return on Equity (ROE)
0.44%
TTM Avg
-17.98%
3Y Avg
71.24%
5Y Avg
-6.51%
Market Cap
$573.32M
Return on Equity (ROE)
-60.79%
TTM Avg
-73.94%
3Y Avg
-62.04%
5Y Avg
-71.62%
Market Cap
$534.23M
Return on Equity (ROE)
-17.44%
TTM Avg
-97.25%
3Y Avg
-87.77%
5Y Avg
-77.06%
Market Cap
$583.05M
Return on Equity (ROE)
-11.56%
TTM Avg
-11.05%
3Y Avg
-6.83%
5Y Avg
-8.10%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| CytomX Therapeutics, Inc. (CTMX) | $557.41M | -26.37% | 0.74% | 28.30% | -66.09% |
| MiniMed Group, Inc. (MMEDV)vs › | $560.00M | N/A | N/A | N/A | N/A |
| CorMedix Inc. (CRMD)vs › | $564.07M | 40.62% | 9.52% | -25.24% | -32.61% |
| Aquestive Therapeutics, Inc. (AQST)vs › | $566.48M | N/A | 161.13% | 93.89% | 96.07% |
| BlossomHill Therapeutics, Inc. (BLSM)vs › | $570.28M | N/A | 44.05% | 44.05% | 44.05% |
| Delcath Systems, Inc. (DCTH)vs › | $541.64M | 0.44% | -17.98% | 71.24% | -6.51% |
| Aclaris Therapeutics, Inc. (ACRS)vs › | $573.32M | -60.79% | -73.94% | -62.04% | -71.62% |
| Immix Biopharma, Inc. (IMMX)vs › | $534.23M | -17.44% | -97.25% | -87.77% | -77.06% |
| OrthoPediatrics Corp. (KIDS)vs › | $583.05M | -11.56% | -11.05% | -6.83% | -8.10% |
| Crescent Biopharma, Inc. (CBIO)vs › | $530.79M | -99.83% | 118.83% | 8.21% | -14.12% |
ROE
-26.4%
ROA
-20.9%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -26.37% |
| 2026-03-31 | -18.48% |
| 2025-12-31 | -17.54% |
| 2025-09-30 | 26.09% |
| 2025-06-30 | 40.02% |
| 2025-03-31 | 166.09% |
| 2022-09-30 | -410.09% |
| 2022-06-30 | -226.43% |
| 2022-03-31 | -146.69% |
| 2021-09-30 | -64.55% |
| 2021-06-30 | -49.03% |
| 2021-03-31 | -41.53% |
| 2020-09-30 | -111.60% |
| 2020-06-30 | -106.46% |
| 2020-03-31 | -108.81% |
| 2019-12-31 | -200.03% |
| 2019-09-30 | -120.59% |
| 2019-06-30 | -97.29% |
| 2019-03-31 | -67.91% |
| 2018-12-31 | -64.64% |
| 2018-09-30 | -32.82% |
| 2018-06-30 | -93.76% |
| 2018-03-31 | -101.39% |
| 2017-12-31 | -61.66% |
| 2017-09-30 | -126.99% |
| 2017-06-30 | -119.01% |
| 2017-03-31 | -69.29% |
| 2016-12-31 | -75.05% |
| 2016-09-30 | -63.02% |
| 2016-06-30 | -52.93% |
| 2016-03-31 | -40.09% |
| 2015-12-31 | -28.06% |
| 2015-06-30 | -32.06% |
